Colorectal Cancer | Specialty

New Molecular Testing Guidelines Pending for Colorectal Cancer

July 8th 2015

All patients with colorectal cancer being considered for treatment with the EGFR inhibitors cetuximab and panitumumab should undergo extended RAS mutational testing to predict their response to the drugs.

Second-Line Cetuximab Shows PFS Benefit in Wild-Type mCRC

July 4th 2015

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

July 4th 2015

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR

July 4th 2015

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Regorafenib Benefits Consistent in "Real World" mCRC Population

July 3rd 2015

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

Improved OS, PFS Demonstrated by TAS-102, Regardless of KRAS Status

July 3rd 2015

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

Adding Aprepitant Improves Control of Oxaliplatin-Related Nausea, Vomiting in CRC

July 3rd 2015

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

Dr. Dirk Arnold on Sirflox Study Results in Colorectal Cancer

July 2nd 2015

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.

Low BMI Prognostic for Worse Survival in Colorectal Cancer

July 1st 2015

Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.

Dr. Zafar on Low BMI Impact on Colorectal Cancer Survival

July 1st 2015

S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the potential link between low body mass index (BMI) and survival outcomes in metastatic colorectal cancer.

Panitumumab in CRC, Ramucirumab in HCC, 13th ICML, and More

June 26th 2015

Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

June 25th 2015

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

Case Study: 33-Year-Old With Liver-Metastatic Colorectal Cancer

June 25th 2015

Radiofrequency Ablation in Colorectal Cancer Liver Metastases

June 25th 2015

SIRFLOX Study in Liver-Metastatic Colorectal Cancer

June 25th 2015

Radioembolization for CRC Liver Metastases

June 25th 2015

RAS Mutation Status in Colorectal Cancer

June 25th 2015

Liver Resectability in Metastatic Colorectal Cancer

June 25th 2015

Treating Liver Metastases in Colorectal Cancer

June 25th 2015

Controlling Liver Metastases in Colorectal Cancer

June 25th 2015